Randomized Phase III SIERRA Trial of <sup>131</sup> I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML - Concepedia

Concepedia

Publication | Open Access

Randomized Phase III SIERRA Trial of <sup>131</sup> I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML

DOI Full Paper Access

12

Citations

16

References

2024

Year

Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Camille N. Abboud, Nebu Koshy, Patrick J. Stiff, Benjamin Tomlinson, Sunil Abhyankar,

Journal of Clinical Oncology

Abstract

The <sup>131</sup>I-apamistamab-led regimen was associated with a higher dCR rate than conventional care in older patients with RR AML. <sup>131</sup>I-apamistamab was well tolerated and could address an unmet need in this population.

References

	Year	Citations

Page 1